Skip to main content
Premium Trial:

Request an Annual Quote

Innovent Biologics, Merck KGaA to Study IBI351, Erbitux Combo in KRAS-Mutant NSCLC Patients in China

NEW YORK – Innovent Biologics said on Thursday that it has partnered with Merck KGaA to study IBI351 plus Erbitux (cetuximab) in a Phase Ib trial in China enrolling newly diagnosed advanced non-small cell lung cancer patients whose tumors harbor KRAS G12C mutations.

For its part of the collaboration, Jiangsu, China-based Innovent will conduct the study, and Darmstadt, Germany-based Merck KGaA will provide the clinical supply of the EGFR-targeting agent Erbitux, which Eli Lilly develops in the US and Canada.

Separately, Innovent is already conducting a clinical trial of IBI351, which is being developed outside of China, Hong Kong, Macau, and Taiwan by GenFleet Therapeutics under the name GFH925, as a monotherapy in previously treated advanced NSCLC patients harboring KRAS G12C mutations. Based on that single-arm trial, Innovent expects to file a new drug application in China by the end of this year.

The drugmaker is also evaluating the agent plus its PD-1 inhibitor Tyvyt (sintilimab) for advanced KRAS G12C-mutated NSCLC patients who have not received prior treatment.